Celcuity (NASDAQ:CELC) Issues Earnings Results, Misses Estimates By $0.28 EPS

Celcuity (NASDAQ:CELC) issued its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28), Zacks reports.

Here are the key takeaways from Celcuity’s conference call:

• REVTORPYK was FDA-approved for HR-positive, HER2-negative advanced breast cancer without detected PIK3CA mutations, and both its doublet and triplet regimens received preferred Category 1 recommendations in the NCCN guidelines.
• In the PIK3CA-mutant VIKTORIA-1 cohort, gedatolisib-based regimens significantly improved median progression-free survival to approximately 11 months versus 5.6 months for alpelisib plus fulvestrant, while treatment discontinuation due to adverse events was lower for gedatolisib. Celcuity plans to submit an sNDA in the third quarter of 2026.
• Celcuity remains confident that commercial shipments will begin in late Q3 2026. The company has completed its commercial infrastructure, deployed 88 oncology sales specialists, begun an expanded-access program, and estimates a U.S. addressable market exceeding $6 billion annually.
• The VIKTORIA-2 first-line breast cancer program has been expanded to include endocrine-sensitive patients, potentially broadening gedatolisib’s use across most newly diagnosed advanced HR-positive, HER2-negative patients. Celcuity also expects to provide additional prostate cancer data in Q4 2026.
• Second-quarter net loss widened to $78.9 million from $45.3 million year over year, while selling, general and administrative expenses rose sharply due to launch preparation. The company ended June with $754 million in cash and investments and expects funding into 2029, helped by a $575 million convertible-note offering.

Celcuity Stock Down 3.5%

NASDAQ CELC traded down $3.28 on Friday, reaching $89.96. The company had a trading volume of 91,450 shares, compared to its average volume of 1,084,873. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The firm has a 50-day moving average of $94.63 and a 200-day moving average of $107.28. The firm has a market capitalization of $4.40 billion, a PE ratio of -20.92 and a beta of 0.20.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CELC. Invesco Ltd. grew its holdings in Celcuity by 4.9% during the 4th quarter. Invesco Ltd. now owns 147,938 shares of the company’s stock valued at $14,755,000 after purchasing an additional 6,928 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Celcuity in the 4th quarter worth $376,000. KVP Capital Advisors LP purchased a new position in Celcuity in the 4th quarter valued at about $399,000. XTX Topco Ltd grew its stake in shares of Celcuity by 16.3% during the fourth quarter. XTX Topco Ltd now owns 13,275 shares of the company’s stock valued at $1,324,000 after acquiring an additional 1,862 shares in the last quarter. Finally, Ikarian Capital LLC purchased a new position in Celcuity in the fourth quarter valued at about $10,527,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CELC shares. Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research note on Thursday, May 28th. Craig Hallum reissued a “buy” rating and set a $178.00 target price on shares of Celcuity in a research report on Wednesday, July 15th. HC Wainwright restated a “buy” rating and issued a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. Wells Fargo & Company reduced their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Finally, Leerink Partners set a $155.00 price objective on shares of Celcuity in a research note on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.55.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.